rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

FMR LLC

10% owner and Other role

Company insider

Files Form 4 as: 10% owner and Other, Structure Therapeutics; 10% owner and Other, Beam Therapeutics; 10% owner and Other, Avalyn Pharma; 10% owner and Other, Metsera; 10% owner and Other, Sana Biotechnology; Other, Bicara Therapeutics; 10% owner and Other, Fidelity Private Credit Fund; Other, Neumora Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
780
Buys
11
Sells
159
Bought
$29.1M
Sold
$216.2M
Companies
38
Companies where not an officer
38
First trade
6 Jul 2009
Last trade
22 Jul 2026
Last filed
24 Jul 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
GPCR Structure Therapeutics10% owner, Other · Biotechnology · last 22 Jul 20260 buys · 0 sells
BEAM Beam Therapeutics10% owner, Other · Genomics & Gene Editing · last 26 Jun 20260 buys · 9 sells
AVLN Avalyn Pharma10% owner, Other · Biotechnology · last 1 May 20260 buys · 0 sells
Metsera10% owner, Other · last 13 Nov 20250 buys · 2 sells
SANA Sana Biotechnology10% owner, Other · Biotechnology · last 8 Jan 20250 buys · 1 sell
BCAX Bicara TherapeuticsOther · Biotechnology · last 16 Sep 20240 buys · 0 sells
Fidelity Private Credit Fund10% owner, Other · last 29 Nov 20232 buys · 0 sells
NMRA Neumora TherapeuticsOther · Biotechnology · last 19 Sep 20230 buys · 0 sells
Turnstone Biologics10% owner, Other · last 25 Jul 20230 buys · 0 sells
PRME Prime MedicineOther · Biotechnology · last 24 Oct 20220 buys · 0 sells
Verve TherapeuticsOther · last 12 Jul 20220 buys · 9 sells
XLO Xilio TherapeuticsOther · Biotechnology · last 26 Oct 20210 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
22 Jul 2026filed 24 Jul 2026GPCR Structure Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code S$68K1,367 at $50.07filing
22 Jul 2026filed 24 Jul 2026GPCR Structure Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code S$805K16,085 at $50.07filing
22 Jul 2026filed 24 Jul 2026GPCR Structure Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code S$68K1,367 at $50.07filing
22 Jul 2026filed 24 Jul 2026GPCR Structure Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code S$805K16,085 at $50.07filing
26 Jun 2026filed 29 Jun 2026BEAM Beam TherapeuticsGenomics & Gene EditingSEC FORM 4 Sold$8.9M251,488 at $35.26filing
26 Jun 2026filed 29 Jun 2026BEAM Beam TherapeuticsGenomics & Gene EditingSEC FORM 4 Sold$8.9M251,488 at $35.26filing
25 Jun 2026filed 29 Jun 2026BEAM Beam TherapeuticsGenomics & Gene EditingSEC FORM 4 Sold$1.2M33,372 at $35.12filing
25 Jun 2026filed 29 Jun 2026BEAM Beam TherapeuticsGenomics & Gene EditingSEC FORM 4 Sold$1.2M33,372 at $35.12filing
1 May 2026filed 5 May 2026AVLN Avalyn PharmaBiotechnologySEC FORM 4 Code C—727,585filing
1 May 2026filed 5 May 2026AVLN Avalyn Pharmaoption or derivative · BiotechnologySEC FORM 4 Code C—377,948filing
1 May 2026filed 5 May 2026AVLN Avalyn PharmaBiotechnologySEC FORM 4 Code C—80,291filing
1 May 2026filed 5 May 2026AVLN Avalyn PharmaBiotechnologySEC FORM 4 Code C—872,868filing
1 May 2026filed 5 May 2026AVLN Avalyn Pharmaoption or derivative · BiotechnologySEC FORM 4 Code C—727,585filing
1 May 2026filed 5 May 2026AVLN Avalyn Pharmaoption or derivative · BiotechnologySEC FORM 4 Code C—80,291filing
1 May 2026filed 5 May 2026AVLN Avalyn Pharmaoption or derivative · BiotechnologySEC FORM 4 Code C—872,868filing
1 May 2026filed 5 May 2026AVLN Avalyn Pharmaoption or derivative · BiotechnologySEC FORM 4 Code C—225,843filing
1 May 2026filed 5 May 2026AVLN Avalyn Pharmaoption or derivative · BiotechnologySEC FORM 4 Code C—377,948filing
1 May 2026filed 5 May 2026AVLN Avalyn PharmaBiotechnologySEC FORM 4 Code C—225,843filing
1 May 2026filed 5 May 2026AVLN Avalyn PharmaBiotechnologySEC FORM 4 Code C—377,948filing
1 May 2026filed 5 May 2026AVLN Avalyn Pharmaoption or derivative · BiotechnologySEC FORM 4 Code C—727,585filing

The newest 500 lines are listed; the numbers count every line.

Sectors

Health Care89
Industrials1
Not placed80

Buys in green, sells in red, by the company’s sector.

Related people

John M. EvansCEO · CEO at Beam Therapeutics, filing Form 4 there in the last year
Bethany J. CavanaghSVP, Finance and Treasurer · SVP, Finance and Treasurer at Beam Therapeutics, filing Form 4 there in the last year
Giuseppe CiaramellaPresident · President at Beam Therapeutics, filing Form 4 there in the last year
Crespo Blas CollChief Medical Officer · Chief Medical Officer at Structure Therapeutics, filing Form 4 there in the last year
Robert J. MeyerDirector · Director at Avalyn Pharma, filing Form 4 there in the last year
Howard HornChief Financial Officer · Also traded RARE in the last 90 days
Norman P. TaffePresident Generac Home · Also traded GNRC in the last 90 days
Kyle Andrew RaabePresident, Home Power Gen. · Also traded GNRC in the last 90 days